Hoth Therapeutics Partners with OnTargetx to Advance Cancer Therapy HT-KIT

• Hoth Therapeutics Inc. has partnered with OnTargetx R&D Inc. to accelerate research on its preclinical cancer therapeutic, HT-KIT.

• The study, conducted with Charles River Laboratories Montreal ULC, aims to refine immunohistochemistry methods and support the therapeutic’s development.

Hoth Therapeutics Inc., a biopharmaceutical company focused on developing therapies for unmet medical needs, has announced a collaboration with OnTargetx R&D Inc. to further research on its cancer-fighting candidate, HT-KIT. The study represents a key phase in the preclinical development of HT-KIT, which targets c-Kit, a receptor tyrosine kinase linked to various cancers.

The research, carried out in partnership with Charles River Laboratories Montreal ULC, focuses on developing optimized staining methods for c-Kit markers, a crucial element in the HT-KIT therapeutic mechanism. Additionally, tissue samples will be processed and evaluated by a board-certified pathologist to assess the presence of these markers, providing insights that will guide further development.

Comprehensive analysis and reporting from this study will play a critical role in shaping HT-KIT’s future as a potential precision oncology therapy. The initiative aligns with Hoth Therapeutics’ mission to accelerate groundbreaking treatments for cancer patients.

“This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments,” said Robb Knie, CEO of Hoth Therapeutics. “We are committed to driving innovative solutions that can transform patient care.”